Amelenodor by AbbVie for Crohn’s Disease (Regional Enteritis): Likelihood of Approval
This notes a new oral investigational drug (Amelenodor/NX-13) in Phase I for Crohn’s and ulcerative colitis and highlights industry predictions about its chances of advancing. People with IBD may want to know about...